Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2020

View Archived Issues

Epigenetic resistance to PARP inhibitors

Microglial pruning under the influence links alcohol to anxiety

Hoth reports research findings on ability of HT-003 to block acne pathogenic gene expression

Australian researchers uncover critical aspects of MR1 protein to boost immune system

FDA clears IND application for ANK-700

Shouyao Holdings describes new FGFR-4 inhibitors

New baculoviral IAP repeat-containing protein 5 inhibitors patented by Trillium Therapeutics

Popular opinion correct on fear, anxiety

Pivotal phase III CheckMate-274 study of Opdivo meets primary endpoints

FDA clears new IND for ADXS-504

Voronoi synthesizes new dual specificity protein kinase TTK inhibitors

Sichuan Kelun-Biotech Biopharmaceutical discovers PRMT5 inhibitors

IL-20 blockade can be a promising treatment for PDAC, synergizing with anti-PD-1 therapy

New phosphatidylserine synthase inhibitors disclosed by Daiichi Sankyo

Enhertu approved in Japan for HER2-positive metastatic gastric cancer

Novavax initiates U.K. phase III study of NVX-CoV2373 COVID-19 vaccine candidate

Japan first to approve Ecclock for primary axillary hyperhidrosis

Clinical activity seen with SNS-301 and pembrolizumab in head and neck cancer trial

Serum Fetuin-B as potential biomarker of metabolic syndrome and insulin resistance

Phase II trial reveals activity of retifanlimab in chemotherapy-naive Merkel cell carcinoma

FDA approves Nucala for hypereosinophilic syndrome

Basilea initiates phase I/II study of derazantinib in advanced gastric cancer

Ayvakyt approved in E.U. for unresectable or metastatic PDGFRA D842V mutant GIST

Jyseleca receives E.U. approval for moderate to severe active rheumatoid arthritis

Lenvatinib effective in combo with pembrolizumab in PD-L1-refractory melanoma

FDA clears IND for phase II study of Stemedica's itMSCs for COVID-19

ImmVira studies T-3011 in phase I for advanced cutaneous or subcutaneous malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....